The following institutions are conducting studies using the iVYDAL products:
The following studies that evaluate the iVYDAL In Vitro Diagnostics® products have already been published inrecognized international scientific journals:
- First clinical trial evaluating the clinical utility of the determination of GIP in stool samples: Comino et al.. Fecal gluten peptides reveal limitations of serological test and food questionnaires for monitoring gluten-free diet in celiac disease patients. American Journal of Gastroenterology. 2016; 10.1038/agj.2016.439.
- First study using our GIP detection technology in urine samples: Moreno et al.. Detection of gluten immunogenic peptides in the urine of patients with coeliac disease reveals transgressions in the gluten-free diet and incomplete mucosal healing. Gut, (2015) gutjnl-2015-310148.
- Study comparing GIP determination in stool samples with other methods to follow gluten free diet adherence in celiac patients.sasGerasimidis K et al. Comparison of Clinical Methods with the Faecal Gluten Immunogenic Peptide to Assess Gluten Intake in Coeliac Disease. J Pediatr Gastroenterol Nutr. 2018 Jun 18.
- Recommendations about the parameters to be measured in clinical trials about celiac disease made by experts. They include the determination of GIP in stool and urine samples. Ludvigsson et al. Outcome measures in coeliac disease trials: the Tampere recommendations. Gut. 2018 Aug;67(8):1410-1424.
- Review about the different markers for gluten free diet monitoring in celiac patients. Moreno et al. Biomarkers to Monitor Gluten-Free Diet Compliance in Celiac Patients. Nutrients. 2017 Jan 6;9(1). pii: E46.
- First study using our GIP detection technology in stool samples: Comino et al.. Monitoring of gluten-free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces. J. Clin. Nutr.2012; 95(3): 670-677.
- First publication using antibodies specifically designed for the toxic peptide of gluten: Morón et al.. Sensitive detection of cereal fractions that are toxic to celiac disease patients by using monoclonal antibodies to a main immunogenic wheat peptide. Am. J. Clin. Nutr. 2008; 87:405-414.